Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1581178
Sentiment: neutral
Topics: 6-K, regulatory-filing, press-release
TL;DR
Eupraxia Pharma dropped a 6-K on Oct 10th with a press release, check it out.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 10, 2024, reporting information for the month of October 2024. The filing includes Exhibit 99.1, which is a press release dated October 10, 2024. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' activities and may contain important information for investors regarding the company's operations and disclosures.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- October 10, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4 (location) — Principal executive office address
FAQ
What type of report is Eupraxia Pharmaceuticals Inc. filing?
Eupraxia Pharmaceuticals Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What is the filing date of this Form 6-K?
The Form 6-K was filed on October 10, 2024.
What is included as part of this report?
Exhibit 99.1, a Press Release dated October 10, 2024, is included as part of this report.
Where is Eupraxia Pharmaceuticals Inc.'s principal executive office located?
The company's principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Who signed this report on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed the report on behalf of Eupraxia Pharmaceuticals Inc.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-10-10 07:01:01
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 17KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001204.txt ( ) — 61KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: October 10, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer